Barrow Hanley Mewhinney & Strauss LLC Acquires 14,542 Shares of Cabot Co. (NYSE:CBT)

Barrow Hanley Mewhinney & Strauss LLC raised its holdings in Cabot Co. (NYSE:CBT - Free Report) by 2.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 759,250 shares of the specialty chemicals company's stock after buying an additional 14,542 shares during the quarter. Barrow Hanley Mewhinney & Strauss LLC owned 1.35% of Cabot worth $58,189,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. FMR LLC boosted its stake in shares of Cabot by 27.2% in the 1st quarter. FMR LLC now owns 4,696,088 shares of the specialty chemicals company's stock valued at $359,908,000 after purchasing an additional 1,004,962 shares in the last quarter. BlackRock Inc. lifted its position in Cabot by 11.0% during the 1st quarter. BlackRock Inc. now owns 6,931,530 shares of the specialty chemicals company's stock worth $474,186,000 after buying an additional 686,769 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in Cabot by 237.4% during the 2nd quarter. Goldman Sachs Group Inc. now owns 600,154 shares of the specialty chemicals company's stock worth $38,284,000 after buying an additional 422,273 shares in the last quarter. Vanguard Group Inc. lifted its position in Cabot by 6.5% during the 1st quarter. Vanguard Group Inc. now owns 6,120,453 shares of the specialty chemicals company's stock worth $418,701,000 after buying an additional 374,834 shares in the last quarter. Finally, Wellington Management Group LLP lifted its position in Cabot by 11.1% during the 1st quarter. Wellington Management Group LLP now owns 3,541,491 shares of the specialty chemicals company's stock worth $242,273,000 after buying an additional 353,154 shares in the last quarter. Institutional investors own 91.03% of the company's stock.

Cabot stock traded up $0.44 during trading hours on Friday, reaching $69.68. 46,904 shares of the company's stock traded hands, compared to its average volume of 304,332. The company has a debt-to-equity ratio of 0.86, a quick ratio of 1.37 and a current ratio of 2.17. The firm has a market capitalization of $3.90 billion, a price-to-earnings ratio of 13.10, a PEG ratio of 2.71 and a beta of 1.29. The firm's 50 day moving average is $68.57 and its 200-day moving average is $72.21. Cabot Co. has a fifty-two week low of $60.50 and a fifty-two week high of $83.74.

Cabot (NYSE:CBT - Get Free Report) last announced its quarterly earnings results on Monday, August 7th. The specialty chemicals company reported $1.42 EPS for the quarter, missing analysts' consensus estimates of $1.56 by ($0.14). The company had revenue of $968.00 million during the quarter, compared to the consensus estimate of $1.09 billion. Cabot had a net margin of 7.48% and a return on equity of 25.98%. The business's revenue was down 15.8% compared to the same quarter last year. During the same period last year, the company earned $1.73 earnings per share. On average, analysts predict that Cabot Co. will post 5.2 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, September 8th. Stockholders of record on Friday, August 25th will be paid a $0.40 dividend. The ex-dividend date is Thursday, August 24th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.30%. Cabot's dividend payout ratio (DPR) is presently 30.25%.

Several research analysts recently issued reports on CBT shares. JPMorgan Chase & Co. upped their price target on shares of Cabot from $68.00 to $70.00 and gave the stock a "neutral" rating in a research report on Friday, August 11th. Deutsche Bank Aktiengesellschaft reduced their price target on shares of Cabot from $90.00 to $80.00 in a research report on Thursday, May 18th. StockNews.com initiated coverage on shares of Cabot in a research report on Thursday, August 17th. They set a "buy" rating on the stock. Credit Suisse Group cut their target price on shares of Cabot from $85.00 to $82.00 and set an "outperform" rating on the stock in a research report on Tuesday, August 8th. Finally, Loop Capital cut their target price on shares of Cabot from $111.00 to $103.00 in a research report on Tuesday, June 20th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $83.75.

Get Our Latest Analysis on Cabot

Cabot Corporation operates as a specialty chemicals and performance materials company. The company operates through two segments, Reinforcement Materials and Performance Chemicals. It offers reinforcing carbons that are used in tires as a rubber reinforcing agent and performance additive, as well as in industrial products, such as hoses, belts, extruded profiles, and molded goods; and engineered elastomer composites solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Before you consider Cabot, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cabot wasn't on the list.

While Cabot currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.